Comparing clinical and laboratory baseline characteristics at initial diagnosis AML patients in the LOX-high group exposed significantly less bone marrow blasts (54% vs. 63%, p < 0.001), lower WBC counts (6.5 GPt/L vs. 26 GPt/L, p < 0.001), and lower serum LDH (389 U/l vs. 5247 U/l, p < 0.001) compared to those patients with low LOX expression, respectively. The gene discussed is LOX; the disease is acute myeloid leukemia.